Down-regulation of angiotensin II by shRNA reduces collagen synthesis in hepatic stellate cells

International Journal of Molecular Medicine

Volumn 25, Issue 5, 2010, Pages 801-806

  Yu, Fu Jun ^a   Dong, Pei Hong ^a   Fan, Xu Fei ^a   Lin, Zhuo ^a   Chen, Yong Ping ^a   Li, Ji ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin II; Hepatic stellate cells; Liver fibrosis; shRNA

Indexed keywords

ANGIOTENSIN II; COLLAGEN; ENZYME; LIPOSOME; MESSENGER RNA; PROTEIN; SHORT HAIRPIN RNA;

ANIMAL CELL; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DOWN REGULATION; EXPRESSION VECTOR; GENE EXPRESSION; GENE SEQUENCE; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; LIVER FIBROSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RNA INTERFERENCE; STELLATE CELL;

ANGIOTENSIN II; ANIMALS; COLLAGEN; DOWN-REGULATION; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; RATS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77951730492     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000407     Document Type: Article

References (28)

1. Abbasoglu O: Liver transplantation: yesterday, today and tomorrow. World J Gastroenterol 14: 3117-3122, 2008.
2. Elsharkawy AM, Oakley F and Mann DA: The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 10: 927-939, 2005. (Pubitemid 41285572)
3. Hasegawa H and Komuro I: The progress of the study of RAAS. Nippon Rinsho 67: 655-661, 2009.
4. Blauwet LA, Ackerman MJ, Edwards WD, Riehle DL and Ommen SR: Myocardial fibrosis in patients with symptomatic obstructive hypertrophic cardiomyopathy: correlation with echocardiographic measurements, sarcomeric genotypes, and pro-left ventricular hypertrophy polymorphisms involving the renin-angiotensin-aldosterone system. Cardiovasc Pathol 18: 262-268, 2009.
5. Remuzzi G, Perico N, Macia M and Ruggenenti P: The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int (Suppl) 99: S57-S65, 2005. (Pubitemid 44324688)
6. Pu Q, Brassard P, Javeshghani DM, Iglarz M, Webb RL, Amiri F and Schiffrin EL: Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP. J Hypertens 26: 322-333, 2008.
7. Gelosa P, Pignieri A, Fändriks L, de Gasparo M, Hallberg A, Banfi C, Castiglioni L, Turolo L, Guerrini U, Tremoli E and Sironi L: Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens 27: 2444-2451, 2009.
8. Warner FJ, Lubel JS, McCaughan GW and Angus PW: Liver fibrosis: a balance of ACEs? Clin Sci 113: 109-118, 2007.
9. Töx U and Steffen HM: Impact of inhibitors of the Renin-angiotensin-aldosterone system on liver fibrosis and portal hypertension. Curr Med Chem 13: 3649-3661, 2006. (Pubitemid 44873736)
10. Yoshiji H, Noguchi R and Fukui H: RAAS inhibitors as therapeutic alternatives in the treatment of chronic liver diseases. Nippon Rinsho 67: 799-806, 2009.
11. Kuiper JJ, Boomsma F, van Buren H, de Man R, Danser AH and van den Meiracker AH: Components of the renin-angiotensin-aldosterone system in plasma and ascites in hepatic cirrhosis. Eur J Clin Invest 38: 939-944, 2008.
12. Li X, Meng Y, Wu P, Zhang Z and Yang X: Angiotensin II and Aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat. Regul Pept 138: 15-25, 2007. (Pubitemid 44918126)
13. Lee SK and Kumar P: Conditional RNAi towards a silent gene therapy. Adv Drug Deliv Rev 61: 650-664, 2009.
14. Birmingham A, Anderson E, Sullivan K, Reynolds A, Boese Q, Leake D, Karpilow J and Khvorova A: A protocol for designing siRNAs with high functionality and specificity. Nat Protoc 2: 2068-2078, 2007. (Pubitemid 351565844)
15. Grinberg D: Recent patents relating to siRNAs and therapeutic strategies for genetic diseases. Recent Pat DNA Gene Seq 2: 40-43, 2008.
16. López-Fraga M, Wright N and Jiménez A: RNA interference-based therapeutics: new strategies to fight infectious disease. Infect Disord Drug Targets 8: 262-273, 2008.
17. Takeshita F and Ochiya T: Therapeutic potential of RNA interference against cancer. Cancer Sci 97: 689-696, 2006. (Pubitemid 43983779)
18. Gressner AM and Weiskirchen R: Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 10: 76-99, 2006.
19. Wynn TA: Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199-210, 2008.
20. Das SK and Vasudevan DM: Genesis of hepatic fibrosis and its biochemical markers. Scand J Clin Lab Invest 68: 260-269, 2008.
21. Liu J, Gong H, Zhang ZT and Wang Y: Effect of angiotensin II and angiotensin II type 1 receptor antagonist on the proliferation, contraction and collagen synthesis in rat hepatic stellate cells. Chin Med J 121: 161-165, 2008. (Pubitemid 351247891)
22. Yin G, Yan C and Berk BC: Angiotensin II signaling pathways mediated by tyrosine kinases. Int J Biochem Cell Biol 35: 780-783, 2003. (Pubitemid 36379319)
23. Yoshinari K, Miyagishi M and Taira K: Effects on RNAi of the tight structure, sequence and position of the targeted region. Nucleic Acids Res 32: 691-699, 2004. (Pubitemid 38263060)
24. Inoue A, Sawata SY and Taira K: Molecular design and delivery of siRNA. J Drug Target 14: 448-455, 2006.
25. Li SD and Huang L: Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.Curr Opin Investig Drugs 9: 1317-1323, 2008.
26. Van Mil A, Doevendans PA and Sluijter JP: The potential of modulating small RNA activity in vivo. Rev Med Chem 9: 235-248, 2009.
27. Li X, Meng Y, Yang XS, Mi LF and Cai SX: ACEI attenuates the progression of CCl4-induced rat hepatic fibrogenesis by inhibiting TGF-ß1, PDGF-BB, NF-kappaB and MMP-2, 9. World J Gastroenterol 11: 4807-4811, 2005. (Pubitemid 41223287)
28. Meier M, Menne J, Park JK, Holtz M, Gueler F, Kirsch T, Schiffer M, Mengel M, Lindschau C, Leitges M and Haller H: Deletion of protein kinase C-epsilon signaling pathway induces glomerulosclerosis and tubulointerstitial fibrosis in vivo. J Am Soc Nephrol 18: 1190-1198, 2007. (Pubitemid 46536905)